Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib

Annals of Hematology

Volumn 89, Issue 7, 2010, Pages 725-731

  Koh, Youngil ^a   Kim, Inho ^a   Yoon, Sung Soo ^a   Kim, Byoung Kook ^a   Kim, Dae Young ^b   Lee, Je Hwan ^b   Lee, Kyoo Hyung ^b   Park, Eunkyung ^c   Kim, Hyeoung Joon ^d   Sohn, Sang Kyun ^e   Joo, Young Don ^f   Kim, Seok Jin ^g   Chung, Jooseop ^h   Shin, Ho Jin ^h   Kim, Sung Hyun ^h   Kim, Chul Soo ⁱ   Song, Hong Suk ^j   Kim, Min Kyoung ^k   Hyun, Myung Soo ^k   Ahn, Jin Seok ^l   Jung, Chul Won ^l   Park, Seonyang ^a   more..

^a Seoul National University Hospital   (South Korea)

^b Asan Medical Center   (South Korea)

^c Chung Ang University   (South Korea)

^d Chonnam National University Medical School   (South Korea)

^e Kyungpook National University Hospital   (South Korea)

^f Inje University College of Medicine   (South Korea)

^g Korea University College of Medicine   (South Korea)

^h Pusan National University Hospital   (South Korea)

ⁱ Inha University Hospital   (South Korea)

^j Dongsan Medical Center   (South Korea)

^k Young Nam University Hospital   (South Korea)

^l Samsung Medical Center   (South Korea)

more..

Author keywords

Chronic myelogenous leukemia; Dose escalation; Imatinib; Molecular response; Suboptimal response

Indexed keywords

BCR ABL PROTEIN; IMATINIB; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; TUMOR MARKER;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; DIARRHEA; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE CRAMP; NAUSEA; NEUTROPENIA; PHASE 4 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; ADOLESCENT; BLAST CELL CRISIS; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BLAST CRISIS; DISEASE-FREE SURVIVAL; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MUTATION; PIPERAZINES; PYRIMIDINES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 77953072695     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-010-0910-8     Document Type: Article

References (23)

1. Baccarani M, Saglio G, Goldman J et al (2006) Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European Leukemia- Net. Blood 108:1809-1820
2. Hughes T (2006) ABL kinase inhibitor therapy for CML: Baseline assessments and response monitoring. Hematology Am Soc Hematol Educ Program 211-218
3. Hochhaus A, Hughes T (2004) Clinical resistance to imatinib: Mechanisms and implications. Hematol Oncol Clin North Am 18:641-656, ix
4. Druker BJ, Guilhot F, O'Brien SG et al (2006) Five-year followup of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408-2417
5. Chu S, Xu H, Shah NP et al (2005) Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 105:2093-2098
6. Corbin AS, La Rosee P, Stoffregen EP et al (2003) Several Bcr- Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 101:4611-4614
7. Morel F, Bris MJ, Herry A et al (2003) Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib. Eur J Haematol 70:235-239
8. Azam M, Latek RR, Daley GQ (2003) Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112:831-843
9. Kantarjian HM, Talpaz M, O'Brien S et al (2003) Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 101:473-475 (Pubitemid 36077567)
10. Kantarjian H, Pasquini R, Hamerschlak N et al (2007) Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: A randomized phase 2 trial. Blood 109:5143-5150 (Pubitemid 46890528)
11. Jabbour E, Cortes JE, Kantarjian HM (2009) Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: What is the optimal strategy? Mayo Clin Proc 84:161-169
12. Hughes TP, Kaeda J, Branford S et al (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349:1423-1432
13. Hughes T, Branford S (2006) Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Rev 20:29-41
14. Cortes J, Talpaz M, O'Brien S et al (2005) Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 11:3425-3432 (Pubitemid 40627896)
15. Kantarjian HM, Giles F, Gattermann N et al (2007) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110: 3540-3546
16. Kantarjian H, Giles F, Wunderle L et al (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354:2542-2551 (Pubitemid 43882350)
17. Talpaz M, Shah NP, Kantarjian H et al (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354:2531-2541 (Pubitemid 43882349)
18. Kantarjian H, Pasquini R, Levy V et al (2009) Dasatinib or highdose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: Two-year follow-up of a randomized phase 2 study (START-R). Cancer 115:4136-4147
19. Kantarjian HM, Larson RA, Guilhot F et al (2009) Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer 115:551-560
20. Alvarado Y, Kantarjian H, O'Brien S et al (2009) Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer 115:3709-3718
21. Soverini S, Colarossi S, Gnani A et al (2006) Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 12:7374-7379
22. Kantarjian HM, Talpaz M, Giles F et al (2006) New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 145:913-923 (Pubitemid 351639967)
23. Jabbour E, Kantarjian HM, Jones D et al (2008) Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood 112:4839-4842